How to Assess Psychosis Risk After Hallucinogen-Related Admission
How should clinicians assess short-term psychosis risk after a hallucinogen-related admission?
Patients presenting after hallucinogen-related admissions may appear to be at high risk for later psychosis based on crude postadmission rates alone. This study shows that much of that apparent risk is explained by preexisting psychiatric disorders and co-occurring substance use, so clinicians need a structured assessment that starts with baseline vulnerability rather than assuming hallucinogen-specific causation.
-
Define the postexposure window carefully
When evaluating psychosis after a hallucinogen-related admission, separate symptoms occurring within 30 days from those occurring later. The study treated psychotic disorder diagnoses arising between 30 days and 6 months after the index admission as the primary outcome because symptoms within 30 days may be classified as substance-induced.
-
Review baseline psychotic disorder history beyond prior admissions
Obtain both outpatient and inpatient history of psychotic disorders before the hallucinogen-related encounter. This matters because baseline psychotic disorders were much more common in the hallucinogen-related cohort than in the nonhallucinogen cohort (19.2% vs 6.3%), and prior psychosis admissions alone captured only a subset of people with baseline psychotic disorders.
-
Screen for other baseline psychiatric comorbidity
Assess for mood disorders, anxiety disorders, and co-occurring substance use disorders before attributing later psychosis risk to hallucinogen exposure. In adjusted models, baseline psychiatric comorbidity drove risk estimates more strongly than hallucinogen-related admission status itself.
-
Assess co-occurring substance use disorders explicitly
Screen specifically for opioid, stimulant, cannabis, and alcohol use disorders because these were common before hallucinogen-related admissions. In the hallucinogen-related cohort, baseline opioid use disorder was present in 22.5%, cannabis-related disorder in 36.6%, stimulant-related disorder in 16.2%, and alcohol use disorder in 28.1%; stimulant and opioid use disorders remained consistent predictors of postindex psychosis in adjusted models.
-
Assume polysubstance involvement is common until clarified
Do not assess the event as isolated hallucinogen exposure unless the history clearly supports that conclusion. Only 695 of 6,184 individuals with at least 1 hallucinogen-related admission had hallucinogen-related admissions without any nonhallucinogen substance-related admissions during enrollment, indicating that broader substance-use complexity is typical.
-
Interpret young age as a marker of diagnostic uncertainty
Be cautious about causal attribution in younger patients because the median age of the hallucinogen-related admissions cohort was 24 years, overlapping the typical age of onset for schizophrenia spectrum disorders. The article notes that prodromal symptoms may precede formal diagnosis by years, so observed temporality may reflect emerging primary illness rather than a substance-specific effect.
-
Do not overinterpret the admission itself as an independent predictor
Use the hallucinogen-related admission as a cue to perform a fuller psychiatric risk assessment, not as proof of elevated independent psychosis risk. Although crude postindex psychosis rates were higher after hallucinogen-related admission, the association with psychosis diagnosis was no longer significant after adjustment for baseline psychiatric history, demographics, and clinical characteristics (HR 0.97, 95% CI 0.95-1.00).
Clinical Considerations
- The study could not distinguish among hallucinogen subtypes, and agents such as PCP and ketamine may have different psychosis risk profiles than classic psychedelics.
- The sample included only individuals with substance-related admissions, so the findings do not generalize to most people who use hallucinogens without requiring acute care.
- Hallucinogen exposure may be underdetected in hospital settings, which could misclassify some psychosis-related hospitalizations as nonhallucinogen cases.
- The main follow-up window was 6 months, which may miss longer-term psychosis outcomes and does not fully resolve prodromal-phase confounding.
Bottom Line
After a hallucinogen-related admission, the most clinically useful next step is a comprehensive assessment of baseline psychosis and co-occurring psychiatric and substance use disorders, because these factors explain much of the apparent short-term psychosis risk.
